Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms

Table 7 Biomarker levels across lymphoma stages (n = 90), mean ± SD

Parameter	Stage I (n = 19)	Stage II (n = 26)	Stage III (n = 7)	Stage IV (n = 38)	P value
SII	22678.1 ± 13309.1	25768.0 ± 4783.7	39278.6 ± 16261.4	37149.0 ± 10837.2	< 0.001b
SIRI	443.6 ± 178.1	373.6 ± 151.9	210.2 ± 142.2	77.52 ± 35.26	< 0.001b
PD-L1/CXCR3 (%)	51.77 ± 18.69	45.62 ± 17.57	35.71 ± 3.45	57.35 ± 13.79	0.002a
PD-1/CXCR3 (%)	12.10 ± 1.71	11.80 ± 1.60	11.10 ± 0.22	12.92 ± 1.06	0.002a
CXCR3/T lymphocytes (%)	51.02 ± 9.99	50.72 ± 9.77	53.29 ± 8.62	53.21 ± 9.16	0.089
CXCR3/classical monocytes (%)	18.58 ± 4.02	18.0 ± 5.90	12.29 ± 5.19	10.63 ± 3.33	< 0.001b
CXCR3/intermediate monocytes (%)	26.53 ± 5.45	24.27 ± 6.50	18.71 ± 5.65	15.37 ± 4.93	< 0.001b
CXCR3/non-classical monocytes (%)	18.84 ± 6.10	18.58 ± 7.03	10.57 ± 6.83	11.45 ± 5.69	< 0.001b

^aP < 0.01.

^bP < 0.001.

SII: Systemic immune-inflammation index; SIRI: Systemic inflammation response index; PD-L1: Programmed death-ligand 1; CXCR3: C-X-C motif chemokine receptor 3; PD-1: Programmed cell death protein 1.